| アブストラクト | BACKGROUND: Characteristics of patients using newer 2(nd) and 3(rd) line antidiabetic drugs in a real-world setting are poorly understood. We described the characteristics of new users of sodium-glucose co-transporter-2 inhibitors (SGLT-2i), dipeptidyl peptidase-4 inhibitors (DPP-4i), and glucagon-like peptide-1 receptor agonists (GLP-1 RA) in Canada and the United Kingdom (UK) between 2016 and 2018. METHODS: We conducted a multi-database cohort study using administrative health databases from 7 Canadian provinces and the UK Clinical Practice Research Datalink. We assembled a base cohort of antidiabetic drug users between 2006 and 2018, from which we constructed 3 cohorts of new users of SGLT-2i, DPP-4i, and GLP-1 RA between 2016 and 2018. RESULTS: Our cohorts included 194,070 new users of DPP-4i, 166,722 new users of SGLT-2i, and 27,719 new users of GLP-1 RA. New users of GLP-1 RA were more likely to be younger (mean +/- SD: 56.7 +/- 12.2 years) than new users of DPP-4i (67.8 +/- 12.3 years) or SGLT-2i (64.4 +/- 11.1 years). In Canada, new users of DPP-4i were more likely to have a history of coronary artery disease (22%) than new users of SGLT-2i (20%) or GLP-1 RA (15%). CONCLUSION: Although SGLT-2i, DPP-4i, and GLP-1 RAs are recommended as 2(nd) or 3(rd) line therapy for type 2 diabetes, important differences exist in the characteristics of users of these drugs. Contrary to existing guidelines, new users of DPP-4i had a higher prevalence of cardiovascular disease at baseline than new users of SGLT2i or GLP-1RA. |
|---|
| 投稿者 | Brunetti, Vanessa C; St-Jean, Audray; Dell'Aniello, Sophie; Fisher, Anat; Yu, Oriana H Y; Bugden, Shawn C; Daigle, Jean-Marc; Hu, Nianping; Alessi-Severini, Silvia; Shah, Baiju R; Ronksley, Paul E; Lix, Lisa M; Ernst, Pierre; Filion, Kristian B |
|---|
| 組織名 | Department of Epidemiology, Biostatistics, and Occupational Health, McGill;University, Montreal, Quebec, Canada.;Center for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital,;3755 Cote Ste Catherine, Suite H410.1, Montreal, Quebec, H3T 1E2, Canada.;Department of Anesthesiology, Pharmacology and Therapeutics, University of;British Columbia, Vancouver, British Columbia, Canada.;Division of Endocrinology, Department of Medicine, Jewish General Hospital,;Quebec, Montreal, Canada.;College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba,;Winnipeg, Manitoba, Canada.;School of Pharmacy, Memorial University of Newfoundland, St John's, Newfoundland;and Labrador, Canada.;Institut national d'excellence en sante et en services sociaux (INESSS), Quebec,;Quebec, Canada.;The Health Quality Council, Saskatoon, Saskatchewan, Canada.;Manitoba Centre for Health Policy, Rady Faculty of Health Sciences, University of;Manitoba, Winnipeg, Manitoba, Canada.;ICES, Toronto, Ontario, Canada.;Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.;Department of Community Health Sciences, Cumming School of Medicine, University;of Calgary, Calgary, Alberta, Canada.;Department of Community Health Sciences, University of Manitoba, Winnipeg,;Manitoba, Canada.;Department of Medicine, McGill University, Quebec, Montreal, Canada.;University, Montreal, Quebec, Canada. kristian.filion@mcgill.ca.;kristian.filion@mcgill.ca. |
|---|
